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Abstract
Angiomyolipoma (AML) arising in the liver is rare and usually benign, but it occasionally has malignant potential.
A 58-year-old man with a liver tumor identified by a previous doctor with features suggestive of hepatocellular
carcinoma on computed tomography (CT) underwent anterior segmentectomy of the liver in 2006. Microscopically,
the tumor was composed of exclusively epithelioid cells that were scatteredly positive for human melanoma black
45 on immunohistochemistry. Accordingly, primary hepatic epithelioid AML (eAML) was diagnosed. The patient was
subsequently referred to our hospital for follow-up after hepatectomy. He had event-free survival for nearly 7 years.
In 2013, two well-defined round nodules were detected in the right lung field by chest CT, and partial pneumonectomy
was performed for diagnosis and treatment. Histological examination of the resected lung tissue showed that it was
morphologically and immunohistochemically identical to his primary hepatic eAML, leading to the diagnosis of
pulmonary metastasis. This paper demonstrates a rare case of malignant hepatic eAML with late recurrence in the lung
after hepatectomy.
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Background
Angiomyolipoma (AML) is a relatively rare mesenchy-
mal tumor. Histologically, it is composed of blood
vessels, adipose tissue, and smooth muscle. AML is
most commonly observed in the kidney, followed by
the liver. The tumor is thought to originate from
pluripotent perivascular epithelioid cells (PECs), al-
though its normal tissue counterpart remains unclear
[1, 2]. PEC is immunopositive for melanocytic and
myogenic markers [3]. In addition, a group of tumors
formed by PEC proliferation has been recognized as
PEComas, firstly described by Bonetti and colleagues
in 1992 [1] and currently recognized by the World
Health Organization [4]. AML is considered a mem-
ber of the PEComa family [4]. AML can be histologi-
cally classified according to the ratio of the three
heterogeneous components, from the classic triphasic
type to a monotypic type [5]. Among the monotypic
types of AML, epithelioid AML (eAML) is predomin-
antly composed of epithelioid cells and does not con-
tain blood vessels or adipose tissue. Although in
general AML has good biological behavior, it can have
malignant potential with distant metastasis, recur-
rence, and associated mortality [6–15]. We describe a
case of malignant hepatic eAML that recurred in the
lung nearly 7 years after hepatectomy for the initial
tumor and review the characteristics of malignant
hepatic AML with recurrence.
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Case presentation
A 58-year-old man was incidentally found to have a
liver tumor measuring 20 mm by abdominal ultrason-
ography during a routine company health examination
in 2004. The tumor grew in size over the next 2 years,
and closer inspections were conducted by a previous
physician in 2006. Enhanced computed tomography
(CT) of the abdomen showed a 70-mm mass with
hemorrhagic and necrotic changes in the right lobe of
the liver (segment 5), with early arterial phase stain-
ing and late phase washout, which seemed to be con-
sistent with hepatocellular carcinoma (HCC) (Fig. 1).
Anterior segmentectomy of the liver was performed.
Macroscopically, non-encapsulated tumor had irregu-
lar borders. Sectioning of resected specimen revealed
a white to yellow, friable, hemorrhagic mass measur-
ing 63 × 50 mm (Fig. 2). Microscopically, hematoxylin
and eosin staining showed atypical epithelioid cells
containing abundant clear to eosinophilic granular
cytoplasm arranged in nests and sheets. The cells
were unevenly distributed and had pleomorphic nuclei
of varying sizes. Blood vessels were inconspicuous
and mature adipose tissue was not detected. Both bile
ducts and portal tracts were involved in the tumor.
Immunohistochemically, the tumor cells were negative
for hepatocyte paraffin 1 (HepPar 1) and alpha feto-
protein. In contrast, the tumor cells were scatteredly
positive for melanocytic markers including human
melanoma black 45 (HMB-45) and Melan A, but
negative for smooth muscle antigen (SMA) and S100
protein, together with negative for c-kit and moder-
ately high Ki-67 labeling index (12.9 %) (Fig. 3).
Accordingly, primary hepatic eAML was diagnosed at
that time.
After hepatectomy, the patient was referred to our
hospital and followed every 6 months on an out-
patient basis. No hepatic recurrence was observed
over nearly 7 years. In 2013, a chest X-ray showed a
well-defined nodule in the right lung field (Fig. 4a).
Chest CT showed two round nodules in segments 1
and 3 of the right lung, measuring 10 and 4 mm, re-
spectively (Fig. 4b, c). Fluorodeoxyglucose-positron
emission tomography did not show any uptake. Since
the diagnosis could not be confirmed by inspection
through bronchoscopy, partial pneumonectomy was
performed for diagnostic and therapeutic purposes.
Macroscopically, the two resected specimens included
solid white masses. Microscopically, the neoplastic
cells were morphologically similar to those of the pri-
mary hepatic tumor. There was no evidence of vascu-
lar invasion. Immunohistochemically, the tumor cells
were diffusely positive for HMB-45 and negative for
SMA and S-100 protein. In addition, the tumor cells
were negative for c-kit and the Ki-67 labeling index
was 9.0 % (Fig. 5). Therefore, a diagnosis of lung me-
tastases from hepatic eAML was made. Loss of tuber-
ous sclerosis complex (TSC) genes, TSC1 and TSC2,
was not detected. The patient has remained
recurrence-free on a closer follow-up schedule for
2 years after pneumonectomy.
Discussion
Since it was first described by Ishak [16] in 1976,
hepatic AML is now a well-recognized tumor. The
Fig. 1 Imaging of primary hepatic AML. a Plain CT showed a low-density mass in segment 5 of the liver. b, c Enhanced CT showed a tumor with
hemorrhagic and necrotic changes, with early arterial phase staining and late phase washout
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number of reports on hepatic AML, including malig-
nant cases, has continued to increase worldwide. In
recent years, the clinicopathological characteristics of
malignant hepatic AML have been intensively investi-
gated despite many challenges. Tumor size has been
reported as a simple and clear predictor of malignant
AML [10–14, 17]. Although the cutoff value varies in
the literature, Ding and colleagues [14] identified that
tumors greater than 60 mm in diameter might have
malignant potential and this was true of our case
(63 mm). In terms of histology, cytologic atypia, pleo-
morphism, necrosis, and high mitotic rate were reported
as predictors of malignant potential [10, 11, 13, 17]. The
presence of cytologic atypia and necrosis are fre-
quently observed in malignant cases, including ours.
However, Nonomura and colleagues [5] demonstrated
that atypia and pleomorphism are occasionally found
in epithelioid cells and does not always indicate ma-
lignant hepatic AML. In addition, the monotypic epi-
thelioid variant of AML arising from the kidney had
been regarded as having malignant potential [18, 19],
whereas data on those of hepatic origin are scarce.
Recently, the number of reports on malignant
classical AML in the liver has also been increasing
[10, 12, 13, 15]. Accumulation of cases is necessary to
clarify the histological differences between malignant
and benign AML.
Immunohistochemically, there was a difference in
the degree of staining for HMB-45 between primary
and metastatic lesion. Considering intratumoral het-
erogeneity has been observed in various malignancies
[20], this difference may suggest malignant potential
in our case. Moreover, a previous investigation
showed that lack of c-kit expression is suggestive of
malignant hepatic AML, [13] in contrast to c-kit
immunopositivity in benign lesions [21]. Indeed, in
four cases where c-kit expression was evaluated, all
were negative or weakly positive. Although further in-
vestigation of the intensity of c-kit staining in malig-
nant cases is required, it is potentially a predictive
marker.
There is a paucity of detailed data on the metastasis
or recurrence pattern of malignant hepatic AML. As
summarized in Table 1, the most frequently observed
site of recurrence is the liver (nine cases), followed by
the lung (three cases), pancreas (two cases), and other
organs, indicating a hematogenous pattern of metasta-
sis for malignant hepatic AML. Furthermore, our case
showed that the lung could be the first site of recur-
rence for malignant hepatic AML. Thus, prudent
evaluation of the lung fields by chest X-ray or chest
CT in addition to following the residual liver should
be conducted.
Four patients died due to disease recurrence,
indicating an unfavorable prognosis after recurrence
[10, 12–14]. In a case described by Dalle and col-
leagues [7], the tumor was observed for 5 years be-
fore it was resected, and multiple metastases appeared
in the residual liver just 5 months after resection.
Moreover, median recurrence-free survival of the ten
patients with recurrence was 36 months (range, 5–
108 months); three patients relapsed more than
Fig. 2 Sections of the resected hepatic AML specimen. The tumor
included a white to yellow solid mass with areas of hemorrhage
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Fig. 3 Pathological findings of hepatic AML. a Hematoxylin and eosin staining showed atypical epithelioid cells containing clear to eosinophilic granular
cytoplasm and pleomorphic nuclei (original magnification ×400). b Immunohistochemical staining was negative for HepPar 1 (original magnification
×200), c scatteredly positive for HMB-45 (original magnification ×200), d inconspicuous for SMA (original magnification ×200), and e negative for c-kit
(mast cells were expressing c-kit; original magnification ×400). f The Ki-67 labeling index was 12.9 % (original magnification ×200)
Fig. 4 Imaging of the recurrent lesions in the lung. a Chest X-ray demonstrated a well-defined nodule in the right upper lung field
(arrow). b, c Chest CT demonstrated two round nodules in segments 1 and 3 of the right lung, respectively (arrow)
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5 years after initial resection. Prompt surgical treat-
ment and careful follow-up for a long period is cru-
cial to increasing the survival of patients with
malignant disease. In addition, our case suggests that
early detection and re-resection of the site of recur-
rence could improve the prognosis of patients with
malignant case.
Conclusions
In conclusion, we reported a case of malignant hep-
atic AML with late recurrence in the lung and exam-
ined the characteristics of recurrence in patients with
malignant hepatic AML. The prognosis of patients
with malignant hepatic AML is poor. In this respect,
we regard hepatic AML as a borderline malignant
tumor, and aggressive therapeutic intervention is rec-
ommended since surgical resection is indisputably the
most reliable curative treatment.
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Fig. 5 Pathological findings of the recurrent lesions in the lung. a Hematoxylin and eosin staining showed that the tumor cells were morphologically
similar to those of the primary hepatic AML tumor (original magnification ×400). b Immunohistochemical staining was diffusely positive for HMB-
45 (original magnification ×200), c negative for SMA (original magnification ×200), and d negative for c-kit (original magnification ×400).
e The Ki-67 labeling index was 9.0 % (original magnification ×200)
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Table 1 Previous reports of malignant hepatic AML with recurrence











1 [7] 70 F 15 + Epithelioid
variant
+ + N/A N/A Liver 5 − Alive with the disease details
were not shown
2 [8] 16 F 12 + Epithelioid
variant
+ N/A N/A N/A Liver 6 + N/A
3 [9] 51 F 10 + Epithelioid
variant
N/A N/A 2 % N/A Liver 36 + Alive without the disease
1.5 years after recurrence
4 [10] 30 M 18 + Classical
AML
+ + 30 % Weakly
+
Liver, pancreas, and lung 36 + Died 4 months after
recurrence
5 [11] 60 F 14 + Epithelioid
variant
− − N/A Weakly
+
Liver, trapezius muscle,
bladder, lung, and pancreas
108 + Alive with the disease details
were not shown
6 [12] 37 F 13 + Classical
AML
+ N/A N/A N/A Liver, lung 6 − Died 8 months after
recurrence
7 [13] 43 F 11 + Classical
AML
+ + Weak − Liver, peritonium,
retroperitonium, and
omentum
6 − Died 3 months after
recurrence
8 [14] 31 F 8 + N/A N/A N/A N/A N/A Liver 72 − Died 1 year after recurrence
9 [15] 37 F 9 + Classical
AML
+ + 4 % N/A Liver 36 +
(transplantation)
Alive without the disease
details were not shown
Present
case
58 M 6.3 + Epithelioid
variant
+ + 13 % Weakly
+
Lung 84 + Alive without the disease
2 years after recurrence
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